Breathe Easy Therapeutics is developing a range of cystic fibrosis (CF) specific formulations and medical devices to provide better tools for clinicians and patients dealing with this life shortening illness.
Cystic Fibrosis is a genetic illness affecting the lungs and digestive systems of approximately 75,000 people worldwide. In the US, the life expectancy of a person with CF is around 37 years. CF qualifies as an orphan illness under the FDA drug development framework, which can provide an accelerated pathway to market, US government grants and 7 years of exclusivity in the US and 10 years in Europe.
Breathe Easy is developing a nebulised drug, Citramel™, which can be used on its own or to complement existing CF treatments. Following Phase IIa clinical trials in CF subjects, Breathe Easy is undertaking a dose escalation study in healthy participants and further analysis of the effects of Citramel™ on dissolution of sputum from those with cystic fibrosis and/or bronchiectasis.